Emma Eckernäs
PhD researcher in pharmacokinetics and pharmacodynamics at the University of Gothenburg
Data updated
Research Footprint
Emma Eckernäs appears in 5 tracked papers (2022–2025), most studied alongside DMT and Placebo, across Medicinal Chemistry & Drug Development, Healthy Volunteers and Neuroimaging & Brain Measures.
Most-cited paper: Psychological and physiological effects of extended DMT (39 citations).
Frequent co-authors: Robin Carhart-Harris, Christopher Timmermann and Michael Ashton.
Background & Research
Emma Eckernäs completed doctoral research on the pharmacokinetics and pharmacodynamics of DMT at the University of Gothenburg’s Institute of Neuroscience and Physiology. Her work has focused on how DMT exposure relates to subjective psychedelic intensity, EEG changes, metabolism, and infusion dosing strategies, often in collaboration with psychedelic researchers at Imperial College London. She has also coauthored clinical and neuroimaging studies on extended DMT administration and network-level brain effects.
Key Impact
She is a key contributor to modern DMT research, especially on its pharmacokinetics, pharmacodynamics, EEG effects, and dose optimization for psychedelic studies.
Collaboration Network
9 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Emma Eckernäs is associated with.